JP6748579B2 - Ｒｎａ生成を強化する方法及び手段 - Google Patents

Ｒｎａ生成を強化する方法及び手段 Download PDF

Info

Publication number
JP6748579B2
JP6748579B2 JP2016572447A JP2016572447A JP6748579B2 JP 6748579 B2 JP6748579 B2 JP 6748579B2 JP 2016572447 A JP2016572447 A JP 2016572447A JP 2016572447 A JP2016572447 A JP 2016572447A JP 6748579 B2 JP6748579 B2 JP 6748579B2
Authority
JP
Japan
Prior art keywords
rna
sequence
ntp
mix
triphosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016572447A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017517266A5 (enExample
JP2017517266A (ja
Inventor
アニエラ・ヴォホナー
ティルマン・ルース
トーマス・ケッテラー
Original Assignee
キュアバック リアル エステート ゲゼルシャフト ミット ベシュレンクテル ハフツング
キュアバック リアル エステート ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51033109&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6748579(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by キュアバック リアル エステート ゲゼルシャフト ミット ベシュレンクテル ハフツング, キュアバック リアル エステート ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical キュアバック リアル エステート ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2017517266A publication Critical patent/JP2017517266A/ja
Publication of JP2017517266A5 publication Critical patent/JP2017517266A5/ja
Application granted granted Critical
Publication of JP6748579B2 publication Critical patent/JP6748579B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M21/00—Bioreactors or fermenters specially adapted for specific uses
    • C12M21/18—Apparatus specially designed for the use of free, immobilized or carrier-bound enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M23/00—Constructional details, e.g. recesses, hinges
    • C12M23/44—Multiple separable units; Modules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
    • C12M29/04—Filters; Permeable or porous membranes or plates, e.g. dialysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
    • C12M29/14—Pressurized fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
    • C12M29/18—External loop; Means for reintroduction of fermented biomass or liquid percolate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
    • C12M41/26—Means for regulation, monitoring, measurement or control, e.g. flow regulation of pH
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
    • C12M41/30—Means for regulation, monitoring, measurement or control, e.g. flow regulation of concentration
    • C12M41/32—Means for regulation, monitoring, measurement or control, e.g. flow regulation of concentration of substances in solution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
    • C12M41/48—Automatic or computerized control
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Sustainable Development (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Clinical Laboratory Science (AREA)
  • Computer Hardware Design (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016572447A 2014-06-10 2015-06-10 Ｒｎａ生成を強化する方法及び手段 Active JP6748579B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2014001577 2014-06-10
EPPCT/EP2014/001577 2014-06-10
PCT/EP2015/001164 WO2015188933A1 (en) 2014-06-10 2015-06-10 Methods and means for enhancing rna production

Publications (3)

Publication Number Publication Date
JP2017517266A JP2017517266A (ja) 2017-06-29
JP2017517266A5 JP2017517266A5 (enExample) 2018-05-31
JP6748579B2 true JP6748579B2 (ja) 2020-09-02

Family

ID=51033109

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016572447A Active JP6748579B2 (ja) 2014-06-10 2015-06-10 Ｒｎａ生成を強化する方法及び手段

Country Status (15)

Country Link
US (3) US10837039B2 (enExample)
EP (2) EP3521456B1 (enExample)
JP (1) JP6748579B2 (enExample)
KR (1) KR102459599B1 (enExample)
CN (1) CN106661621B (enExample)
AU (1) AU2015273933B2 (enExample)
BR (1) BR112016026980B1 (enExample)
CA (1) CA2945629C (enExample)
ES (1) ES2727776T3 (enExample)
MX (1) MX382298B (enExample)
PL (1) PL3155129T3 (enExample)
PT (1) PT3155129T (enExample)
RU (1) RU2738753C2 (enExample)
SG (1) SG11201608605QA (enExample)
WO (1) WO2015188933A1 (enExample)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
PT2717893T (pt) 2011-06-08 2019-08-20 Translate Bio Inc Composições de nanopartículas lipídicas e métodos para transferência de arnm
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
SG10201607968WA (en) 2012-03-27 2016-12-29 Curevac Ag Artificial nucleic acid molecules for improved protein or peptide expression
CN105073135A (zh) 2013-02-22 2015-11-18 库瑞瓦格有限责任公司 疫苗接种和抑制pd-1途径的组合
CN105209490A (zh) 2013-03-14 2015-12-30 夏尔人类遗传性治疗公司 用于递送mrna编码的抗体的方法和组合物
SMT201800264T1 (it) 2013-03-15 2018-07-17 Translate Bio Inc Potenziamento sinergico del rilascio di acidi nucleici attraverso formulazioni miscelate
AU2014310934B2 (en) 2013-08-21 2019-09-12 CureVac SE Respiratory syncytial virus (RSV) vaccine
CA2915730A1 (en) 2013-08-21 2015-02-26 Karl-Josef Kallen A combination rsv/influenza a vaccine
AU2014310931B2 (en) 2013-08-21 2019-12-19 CureVac SE Rabies vaccine
CA2925021C (en) 2013-11-01 2025-05-06 Curevac Ag MODIFIED MESSENGER RIBONUCLE ACID (MRNA) WITH REDUCED IMMUNOSTIMULATING PROPERTIES
CA2927254C (en) 2013-12-30 2023-10-24 Curevac Ag Artificial nucleic acid molecules
AU2014375404C1 (en) 2013-12-30 2020-11-19 CureVac Manufacturing GmbH Methods for RNA analysis
EP3090060B2 (en) 2013-12-30 2025-05-21 CureVac Manufacturing GmbH Methods for rna analysis
EP3116535B1 (en) 2014-03-12 2019-08-07 CureVac AG Combination of vaccination and ox40 agonists
CA2936286A1 (en) 2014-04-01 2015-10-08 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
CN106661621B (zh) 2014-06-10 2020-11-03 库尔维科公司 用于增强rna产生的方法和工具
WO2016091391A1 (en) 2014-12-12 2016-06-16 Curevac Ag Artificial nucleic acid molecules for improved protein expression
US10653768B2 (en) 2015-04-13 2020-05-19 Curevac Real Estate Gmbh Method for producing RNA compositions
US10780054B2 (en) 2015-04-17 2020-09-22 Curevac Real Estate Gmbh Lyophilization of RNA
US11384375B2 (en) 2015-04-30 2022-07-12 Curevac Ag Immobilized poly(n)polymerase
DK3294885T3 (da) 2015-05-08 2020-08-10 Curevac Real Estate Gmbh Fremgangsmåde til at fremstille rna
RU2742993C2 (ru) 2015-05-15 2021-02-12 Куревак Аг РЕЖИМЫ ПРАЙМ-БУСТ, ВКЛЮЧАЮЩИЕ ВВЕДЕНИЕ ПО МЕНЬШЕЙ МЕРЕ ОДНОЙ КОНСТРУКЦИИ мРНК
US10729654B2 (en) 2015-05-20 2020-08-04 Curevac Ag Dry powder composition comprising long-chain RNA
US10517827B2 (en) 2015-05-20 2019-12-31 Curevac Ag Dry powder composition comprising long-chain RNA
EP4098743A1 (en) 2015-05-29 2022-12-07 CureVac AG Method for adding cap structures to rna using immobilized enzymes
ES2798271T3 (es) 2015-05-29 2020-12-10 Curevac Real Estate Gmbh Método para producir y purificar ARN, que comprende al menos una etapa de filtración de flujo tangencial
US10501768B2 (en) 2015-07-13 2019-12-10 Curevac Ag Method of producing RNA from circular DNA and corresponding template DNA
CN114381470A (zh) 2015-08-28 2022-04-22 库瑞瓦格股份公司 人工核酸分子
EP3362576A1 (en) 2015-10-12 2018-08-22 CureVac AG Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
EP3373965A1 (en) 2015-11-09 2018-09-19 CureVac AG Rotavirus vaccines
CA3009551C (en) 2015-12-22 2022-12-13 Curevac Ag Method for producing rna molecule compositions
EP3394280A1 (en) 2015-12-23 2018-10-31 CureVac AG Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
WO2017140905A1 (en) 2016-02-17 2017-08-24 Curevac Ag Zika virus vaccine
US11920174B2 (en) 2016-03-03 2024-03-05 CureVac SE RNA analysis by total hydrolysis and quantification of released nucleosides
KR102369898B1 (ko) 2016-04-08 2022-03-03 트랜슬레이트 바이오 인코포레이티드 다량체 코딩 핵산 및 그 용도
WO2017186928A1 (en) 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
US12508308B2 (en) 2016-05-04 2025-12-30 CureVac SE Influenza mRNA vaccines
EP4477662A3 (en) 2016-05-04 2025-03-19 CureVac SE Nucleic acid molecules and uses thereof
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
SG11201809912UA (en) 2016-06-09 2018-12-28 Curevac Ag Hybrid carriers for nucleic acid cargo
EP3842530A1 (en) 2016-06-13 2021-06-30 Translate Bio, Inc. Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency
MX2019002904A (es) * 2016-09-14 2019-09-26 Modernatx Inc Composiciones de arn de alta pureza y métodos para su preparación.
US11279923B2 (en) 2016-11-28 2022-03-22 Curevac Ag Method for purifying RNA
EP3548005A4 (en) 2016-11-29 2020-06-17 Puretech Health LLC Exosomes for delivery of therapeutic agents
US11542490B2 (en) 2016-12-08 2023-01-03 CureVac SE RNAs for wound healing
EP3808380A1 (en) 2016-12-08 2021-04-21 CureVac AG Rna for treatment or prophylaxis of a liver disease
US11141476B2 (en) 2016-12-23 2021-10-12 Curevac Ag MERS coronavirus vaccine
WO2018115507A2 (en) 2016-12-23 2018-06-28 Curevac Ag Henipavirus vaccine
EP3558354A1 (en) 2016-12-23 2019-10-30 CureVac AG Lassa virus vaccine
AU2018224387B2 (en) 2017-02-22 2024-08-08 Crispr Therapeutics Ag Compositions and methods for gene editing
MA47607A (fr) * 2017-02-27 2020-01-01 Translate Bio Inc Synthèse à grande échelle d'arn messager
CN110392577A (zh) 2017-03-17 2019-10-29 库尔维科公司 用于组合抗癌疗法的rna疫苗和免疫检查点抑制剂
CA3050616A1 (en) 2017-03-24 2018-09-27 Curevac Ag Nucleic acids encoding crispr-associated proteins and uses thereof
WO2018191657A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
US12474242B2 (en) * 2017-04-21 2025-11-18 The Board Of Trustees Of The Leland Stanford Junior University Exposome tracker for environmental health
US11485969B2 (en) * 2017-04-21 2022-11-01 The Board Of Trustees Of The Leland Stanford Junior University Collector device of environmental exposure for biotic and abiotic agents
WO2018211038A1 (en) 2017-05-17 2018-11-22 Curevac Ag Method for determining at least one quality parameter of an rna sample
RU2020103379A (ru) 2017-07-04 2021-08-04 Куревак Аг Новые молекулы нуклеиновых кислот
US11001868B2 (en) * 2017-08-11 2021-05-11 Global Life Sciences Solutions Operations UK Ltd Cell-free protein expression using double-stranded concatameric DNA
US11602557B2 (en) 2017-08-22 2023-03-14 Cure Vac SE Bunyavirales vaccine
WO2019092153A1 (en) 2017-11-08 2019-05-16 Curevac Ag Rna sequence adaptation
WO2019115635A1 (en) 2017-12-13 2019-06-20 Curevac Ag Flavivirus vaccine
WO2019126593A1 (en) 2017-12-20 2019-06-27 Translate Bio, Inc. Improved composition and methods for treatment of ornithine transcarbamylase deficiency
US11525158B2 (en) 2017-12-21 2022-12-13 CureVac SE Linear double stranded DNA coupled to a single support or a tag and methods for producing said linear double stranded DNA
EP3773702A2 (en) 2018-04-05 2021-02-17 CureVac AG Novel yellow fever nucleic acid molecules for vaccination
US20210170017A1 (en) 2018-04-17 2021-06-10 Curevac Ag Novel rsv rna molecules and compositions for vaccination
WO2020002525A1 (en) 2018-06-27 2020-01-02 Curevac Ag Novel lassa virus rna molecules and compositions for vaccination
CA3102135A1 (en) 2018-06-28 2020-01-02 Curevac Ag Bioreactor for rna in vitro transcription
TW202039534A (zh) 2018-12-14 2020-11-01 美商美國禮來大藥廠 KRAS變體mRNA分子
US12492425B2 (en) 2018-12-21 2025-12-09 CureVac SE Methods for RNA analysis
CA3118034A1 (en) 2018-12-21 2020-06-25 Curevac Ag Rna for malaria vaccines
EP3938507A4 (en) * 2019-03-11 2023-02-22 ModernaTX, Inc. PROCEDURE FOR IN VITRO FED BATCH TRANSCRIPTION
US11578348B2 (en) 2019-04-24 2023-02-14 The University Of Massachusetts Enzymatic methods to generate high yields of sequence specific rna with extreme precision
US12359248B2 (en) 2019-04-24 2025-07-15 University Of Massachusetts Enzymatic methods to generate high yields of sequence specific RNAs with extreme precision
US20220313813A1 (en) 2019-06-18 2022-10-06 Curevac Ag Rotavirus mrna vaccine
CA3144902A1 (en) 2019-08-14 2022-01-19 Andreas Thess Rna combinations and compositions with decreased immunostimulatory properties
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
TW202140518A (zh) 2020-02-04 2021-11-01 德商奎爾法克股份有限公司 冠狀病毒疫苗
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
KR20220162125A (ko) * 2020-02-18 2022-12-07 트랜슬레이트 바이오 인코포레이티드 전령 rna의 시험관 내 전사를 위한 개선된 프로세스
AU2021257344A1 (en) * 2020-04-16 2022-10-13 Nature's Toolbox, Inc. In vitro manufacturing and purification of therapeutic mRNA
CN120099118A (zh) * 2020-05-12 2025-06-06 查拉拉姆波斯·马卡里奥斯 用于合成基于rna的治疗剂的方法和模块化设备
GB2597436B (en) * 2020-05-12 2025-03-26 Makatsoris Charalampos A method and apparatus for RNA synthesis
MX2022015132A (es) 2020-05-29 2023-03-08 CureVac SE Vacunas combinadas a base de acidos nucleicos.
CA3170741A1 (en) 2020-07-31 2022-02-03 Curevac Ag Nucleic acid encoded antibody mixtures
US20240066114A1 (en) 2020-08-31 2024-02-29 CureVac SE Multivalent nucleic acid based coronavirus vaccines
EP4208286A1 (en) 2020-09-01 2023-07-12 CureVac RNA Printer GmbH Manufacturing device for a pharmaceutical product
JP2023540562A (ja) 2020-09-04 2023-09-25 ヴァーヴ・セラピューティクス，インコーポレーテッド Ｒｎａをキャッピングするための組成物および方法
TW202231651A (zh) * 2020-10-15 2022-08-16 美商崔斯雷生物公司 大規模合成訊息ｒｎａ
WO2022084748A1 (en) 2020-10-23 2022-04-28 Spindle Biotech, Inc. Compositions and methods for rna synthesis
CA3193238A1 (en) 2020-11-27 2022-06-02 Benyamin YAZDAN PANAH A device for preparing a dna product by means of capillary polymerase chain reaction
WO2022122689A1 (en) * 2020-12-09 2022-06-16 BioNTech SE Rna manufacturing
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
US20240156946A1 (en) 2020-12-22 2024-05-16 CureVac SE Rna vaccine against sars-cov-2 variants
CN114717229B (zh) * 2021-01-05 2024-09-10 麦塞拿治疗(香港)有限公司 治疗性mRNA的无细胞和无载体体外RNA转录方法和核酸分子
CN114717230B (zh) * 2021-01-05 2024-09-03 麦塞拿治疗(香港)有限公司 成纤维细胞生长因子mRNA的无细胞和无载体体外RNA转录方法和核酸分子
EP4274607A1 (en) 2021-01-11 2023-11-15 ModernaTX, Inc. Seasonal rna influenza virus vaccines
WO2022162027A2 (en) 2021-01-27 2022-08-04 Curevac Ag Method of reducing the immunostimulatory properties of in vitro transcribed rna
WO2022200575A1 (en) 2021-03-26 2022-09-29 Glaxosmithkline Biologicals Sa Immunogenic compositions
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
CA3222975A1 (en) * 2021-06-30 2023-01-05 Etherna Immunotherapies Nv Method for rna manufacturing
TWI814499B (zh) * 2021-07-22 2023-09-01 中央研究院 用以連續製備及分析ｒｎａ的裝置以及利用該裝置來合成ｒｎａ的方法
US20250002524A1 (en) 2021-07-30 2025-01-02 CureVac SE Cap analogs having an acyclic linker to the guanine derivative nucleobase
WO2023025404A1 (en) * 2021-08-24 2023-03-02 BioNTech SE In vitro transcription technologies
WO2023073228A1 (en) 2021-10-29 2023-05-04 CureVac SE Improved circular rna for expressing therapeutic proteins
US12529047B1 (en) 2021-12-21 2026-01-20 Modernatx, Inc. mRNA quantification methods
EP4469091A1 (en) 2022-01-28 2024-12-04 CureVac SE Nucleic acid encoded transcription factor inhibitors
EP4486890A1 (en) 2022-03-01 2025-01-08 CRISPR Therapeutics AG Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
CN119053705A (zh) 2022-03-21 2024-11-29 克里斯珀医疗股份公司 用于治疗脂蛋白相关疾病的方法和组合物
KR20250028547A (ko) 2022-05-25 2025-02-28 큐어백 에스이 대장균 FimH 항원성 폴리펩타이드를 인코딩하는 핵산 기반 백신
CN119947747A (zh) 2022-09-26 2025-05-06 葛兰素史克生物有限公司 流感病毒疫苗
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
WO2024089229A1 (en) 2022-10-28 2024-05-02 CureVac SE Improved formulations comprising lipid-based carriers encapsulating rna
EP4658664A1 (en) 2023-01-31 2025-12-10 CureVac SE Cap analogs with 5'-terminal acyclic guanosine derivative
EP4658239A1 (en) 2023-02-03 2025-12-10 GlaxoSmithKline Biologicals S.A. Rna formulation
GB202302092D0 (en) 2023-02-14 2023-03-29 Glaxosmithkline Biologicals Sa Analytical method
WO2024223728A1 (en) 2023-04-27 2024-10-31 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2024223724A1 (en) 2023-04-27 2024-10-31 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2024235451A1 (en) 2023-05-16 2024-11-21 CureVac RNA Printer GmbH Improved rna in vitro transcription using dna beads
WO2024245907A1 (en) 2023-05-26 2024-12-05 CureVac SE Cancer antigens
WO2025022290A1 (en) 2023-07-21 2025-01-30 Crispr Therapeutics Ag Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene
WO2025035110A1 (en) * 2023-08-10 2025-02-13 Linearx, Inc. Compositions and methods for in vitro transcription
WO2025103803A1 (en) 2023-11-13 2025-05-22 CureVac SE Immunotherapy against neuronal and brain tumors
GB2637389A (en) * 2023-11-24 2025-07-23 Univ Sheffield In vitro transcription method
GB202317972D0 (en) * 2023-11-24 2024-01-10 Univ Sheffield In vitro transcription method
WO2025132839A1 (en) 2023-12-21 2025-06-26 Glaxosmithkline Biologicals Sa Influenza virus vaccines
EP4574990A1 (en) * 2023-12-22 2025-06-25 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Methods and systems for producing peptides and proteins
WO2025181704A2 (en) 2024-02-27 2025-09-04 Crispr Therapeutics Ag Rt editing compositions and methods
WO2025186726A1 (en) 2024-03-05 2025-09-12 Crispr Therapeutics Ag Modulating expression of agt (angiotensinogen) gene
WO2025208142A2 (en) 2024-03-29 2025-10-02 New England Biolabs, Inc. Compositions, kits, and methods for in vitro transcription
GB202404607D0 (en) 2024-03-29 2024-05-15 Glaxosmithkline Biologicals Sa RNA formulation
WO2025217602A1 (en) * 2024-04-12 2025-10-16 Sartorius Bioanalytical Instruments, Inc. Systems and methods for rna transcription

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256555A (en) 1991-12-20 1993-10-26 Ambion, Inc. Compositions and methods for increasing the yields of in vitro RNA transcription and other polynucleotide synthetic reactions
US5434079A (en) 1993-02-12 1995-07-18 The United States Of America As Represented By The Department Of Health And Human Services Apparatus and process for continuous in vitro synthesis of proteins
AU7839594A (en) 1993-09-20 1995-04-10 Regents Of The University Of Colorado, The Strategy for the production of rna from immobilized templates
PT1857122E (pt) 2001-06-05 2011-03-07 Curevac Gmbh Arnm estabilizado com teor de g/c aumentado, codificando para um antigénio viral
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
US7074596B2 (en) 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
DE10240868A1 (de) 2002-09-04 2004-03-18 Artus Gesellschaft für molekularbiologische Diagnostik und Entwicklung mbH Verbesserte Verfahren zur Synthese von Nukleinsäuren
US20050064465A1 (en) 2003-07-02 2005-03-24 Caliper Life Sciences, Inc. Continuous and non-continuous flow bioreactor
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
US20050287539A1 (en) * 2004-06-29 2005-12-29 Emmanuel Labourier Methods and compositions for preparing capped RNA
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
DE102005023170A1 (de) 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
EP4174179B1 (en) 2005-08-23 2025-05-07 The Trustees of the University of Pennsylvania Rna containing modified nucleosides and methods of use thereof
WO2008016473A2 (en) 2006-07-28 2008-02-07 Applera Corporation Dinucleotide mrna cap analogs
DE102006035618A1 (de) 2006-07-31 2008-02-07 Curevac Gmbh Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
DE102006061015A1 (de) 2006-12-22 2008-06-26 Curevac Gmbh Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
PL2167523T3 (pl) 2007-06-19 2014-12-31 Univ Louisiana State Synteza i zastosowanie anty-odwrotnych tiofosforanowych analogów kapu matrycowego RNA
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
CA2710534C (en) 2008-01-31 2018-09-04 Curevac Gmbh Nucleic acids of formula (i) (nuglxmgnnv)a and derivatives thereof as an immunostimulating agent/adjuvant
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
JP2013507943A (ja) * 2009-10-21 2013-03-07 リボックス・ゲーエムベーハー Ｒｎａの指数関数的増幅のための方法およびｒｎａリアクター
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
ES2558106T3 (es) 2010-07-30 2016-02-02 Curevac Ag Formación de complejos de ácidos nucleicos con componentes catiónicos disulfuro-reticulados para la transfección e inmunoestimulación
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
WO2012122413A1 (en) 2011-03-08 2012-09-13 University Of Maryland Baltimore County Microscale bioprocessing system and method for protein manufacturing
PT2717893T (pt) 2011-06-08 2019-08-20 Translate Bio Inc Composições de nanopartículas lipídicas e métodos para transferência de arnm
US9862926B2 (en) * 2011-06-27 2018-01-09 Cellscript, Llc. Inhibition of innate immune response
PL3682905T3 (pl) 2011-10-03 2022-04-04 Modernatx, Inc. Modyfikowane nukleozydy, nukleotydy i kwasy nukleinowe oraz ich zastosowania
US8969545B2 (en) 2011-10-18 2015-03-03 Life Technologies Corporation Alkynyl-derivatized cap analogs, preparation and uses thereof
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
WO2013113325A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
EP2623121A1 (en) 2012-01-31 2013-08-07 Bayer Innovation GmbH Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
WO2013120498A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
SG10201607968WA (en) 2012-03-27 2016-12-29 Curevac Ag Artificial nucleic acid molecules for improved protein or peptide expression
SG11201405545XA (en) 2012-03-27 2014-11-27 Curevac Gmbh Artificial nucleic acid molecules comprising a 5'top utr
US9890391B2 (en) 2012-03-27 2018-02-13 Curevac Ag RNA vector with an open reading frame, an albumin 3′-UTR, and a histone stem loop
WO2013151665A2 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
EP2854857B1 (en) 2012-05-25 2018-11-28 CureVac AG Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
CN105073135A (zh) 2013-02-22 2015-11-18 库瑞瓦格有限责任公司 疫苗接种和抑制pd-1途径的组合
AU2014310931B2 (en) 2013-08-21 2019-12-19 CureVac SE Rabies vaccine
CA2914508A1 (en) 2013-08-21 2015-02-26 Curevac Ag Composition and vaccine for treating lung cancer
AU2014310934B2 (en) 2013-08-21 2019-09-12 CureVac SE Respiratory syncytial virus (RSV) vaccine
MX2016002152A (es) 2013-08-21 2017-01-05 Curevac Ag Metodo para aumentar la expresion de proteinas codificadas por arn.
RU2016109938A (ru) 2013-08-21 2017-09-26 Куревак Аг Композиция и вакцина для лечения рака предстательной железы
CA2915730A1 (en) 2013-08-21 2015-02-26 Karl-Josef Kallen A combination rsv/influenza a vaccine
CA2925021C (en) 2013-11-01 2025-05-06 Curevac Ag MODIFIED MESSENGER RIBONUCLE ACID (MRNA) WITH REDUCED IMMUNOSTIMULATING PROPERTIES
AU2014375404C1 (en) 2013-12-30 2020-11-19 CureVac Manufacturing GmbH Methods for RNA analysis
CA2927254C (en) 2013-12-30 2023-10-24 Curevac Ag Artificial nucleic acid molecules
DK3090053T3 (en) 2013-12-30 2019-02-25 Curevac Ag Artificial nucleic acid molecules
EP3116535B1 (en) 2014-03-12 2019-08-07 CureVac AG Combination of vaccination and ox40 agonists
CA2936286A1 (en) 2014-04-01 2015-10-08 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
CN106661621B (zh) 2014-06-10 2020-11-03 库尔维科公司 用于增强rna产生的方法和工具
WO2016091391A1 (en) 2014-12-12 2016-06-16 Curevac Ag Artificial nucleic acid molecules for improved protein expression
EP3233113A1 (en) 2014-12-16 2017-10-25 CureVac AG Ebolavirus and marburgvirus vaccines
CA2966092A1 (en) 2014-12-30 2016-07-07 Curevac Ag Artificial nucleic acid molecules
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
DK3294885T3 (da) 2015-05-08 2020-08-10 Curevac Real Estate Gmbh Fremgangsmåde til at fremstille rna

Also Published As

Publication number Publication date
US20170114378A1 (en) 2017-04-27
SG11201608605QA (en) 2016-12-29
EP3521456B1 (en) 2023-01-04
BR112016026980B1 (pt) 2022-05-03
PL3155129T3 (pl) 2019-09-30
AU2015273933A1 (en) 2016-11-03
ES2727776T3 (es) 2019-10-18
RU2017100044A (ru) 2018-07-18
CA2945629A1 (en) 2015-12-17
US20210040526A1 (en) 2021-02-11
CA2945629C (en) 2023-08-22
KR20170010797A (ko) 2017-02-01
CN106661621A (zh) 2017-05-10
MX382298B (es) 2025-03-12
RU2738753C2 (ru) 2020-12-16
CN106661621B (zh) 2020-11-03
EP3155129A1 (en) 2017-04-19
PT3155129T (pt) 2019-05-16
AU2015273933B2 (en) 2021-02-11
EP3155129B1 (en) 2019-01-16
BR112016026980A2 (pt) 2017-10-31
RU2017100044A3 (enExample) 2018-09-20
KR102459599B1 (ko) 2022-10-26
WO2015188933A1 (en) 2015-12-17
US20240218412A1 (en) 2024-07-04
EP3521456A1 (en) 2019-08-07
JP2017517266A (ja) 2017-06-29
US10837039B2 (en) 2020-11-17
MX2016016170A (es) 2017-03-28

Similar Documents

Publication Publication Date Title
JP6748579B2 (ja) Ｒｎａ生成を強化する方法及び手段
US20230313268A1 (en) Methods for rna analysis
US11920174B2 (en) RNA analysis by total hydrolysis and quantification of released nucleosides
CN107873055B (zh) 包括至少一个切向流过滤步骤的产生和纯化rna的方法
EP3303575B1 (en) Method for adding cap structures to rna using immobilized enzymes
US20190017100A1 (en) Method for analysis of an rna molecule
EP3394280A1 (en) Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
WO2017009376A1 (en) Method of producing rna from circular dna and corresponding template dna
WO2017140345A1 (en) Method for analyzing by-products of rna in vitro transcription
EP3090060B2 (en) Methods for rna analysis
CN119464283A (zh) 加帽的mRNA及其制备方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180411

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180411

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190204

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190319

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190917

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20200115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200608

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200728

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200807

R150 Certificate of patent or registration of utility model

Ref document number: 6748579

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250